VaxNewMO
Saint Louis, United States · Founded 2017 · $6.6M raised
- Headquarters
- Saint Louis, Missouri
- Employees
- 1–10
- Founded
- 2017
- Business Model
- B2G
- Total Funding
- $6.6M
- Last Round
- $3.0M GrantSep 2023
- Rounds
- 3
About
VaxNewMo is a St. Louis-based bioscience startup developing next-generation conjugate vaccines against infectious diseases, with a lead program targeting pneumococcus — a leading cause of pneumonia, meningitis, and bloodstream infections. The company's proprietary bioconjugation technology uses conjugating enzymes within E. coli to produce vaccines without traditional synthetic chemistry, supported by NIH SBIR Phase II funding.
Summary
VaxNewMO is a Biotech company based in Saint Louis, United States, founded in 2017. It has raised $6.6M in total across 3 rounds, most recently a $3.0M Grant round in Sep 2023. Investors include National Institutes of Health, Arch Grants and BioGenerator Ventures.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...